The first facile optical density-dependent approach for the analysis of doxorubicin, an oncogenic agent accompanied with the co-prescribed drug; paclitaxel

BMC Chemistry

Research

Ahmed Abdulhafez Hamad¹ 

[1] Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, 71524, Assiut, Egypt;

关键词: Optical density;    Taxol;    Doxorubicin, Paclitaxel;    Degradation behavior;    Eco-rating;   

DOI  :  10.1186/s13065-023-00976-5

 received in 2022-10-23, accepted in 2023-05-30,  发布年份 2023

来源: Springer

【 摘 要 】

Doxorubicin (DRB) is an anthracycline oncogenic drug extracted from cultures of Streptomyces peucetius var. caesius. It is frequently recommended as an anti-neoplastic agent for the treatment of diverse malignancies. It exerts its antineoplastic effect either via inhibiting the enzyme topoisomerase II and/or via intercalation to DNA or reactive oxygen species generation. In the present article, the direct, simple, one-pot, somewhat eco-safe, and non-extractive spectrophotometric system was executed to track doxorubicin, a chemotherapeutic remedy, in the presence of paclitaxel, a naturally occurring Taxan antineoplastic radical, through the greenness rated method. DRB’s optical density was studied in various mediums and solvents to develop the current approach. An acidic ethanolic solution was found to increase the optical density of the sample significantly. At 480 nm., the most remarkable optical density was obtained. Various experimental factors, including intrinsic media, solvent, pH, and stability time, were investigated and controlled. The current approach achieved linearity within the 0.6–40.0 µg mL-1 range, accompanied by a limit of both detection and quantification (LOD and LOQ) of 0.18 and 0.55 µg mL-1, correspondingly. The approach was validated under the ICH guidelines (Quality Guidelines). The system’s greenness and enhancement degree were estimated.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_259_Article_IEq56.gif

40517_2023_259_Article_IEq86.gif

40517_2023_259_Article_IEq52.gif

40517_2023_259_Article_IEq51.gif

Fig. 2

40517_2023_259_Article_IEq90.gif